CVS Health Corporation — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing, not a standalone fourth-quarter report. The filing incorporates the full MD&A and financial statements by reference; the supplied text does not include those details.
Business context
CVS Health operates Pharmacy Services (PBM and specialty pharmacy), Retail Pharmacy, and Corporate segments. Its integrated business included 7,822 retail drugstores, 971 MinuteClinic locations, and a PBM that filled or managed approximately 932 million prescriptions during 2014. Retail pharmacies filled 756 million prescriptions, approximately 21% of the U.S. retail pharmacy market.
Financial performance
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Net revenue | $139.367 billion | $126.761 billion | +9.9% |
| Gross profit | $25.367 billion | $23.783 billion | +6.7% |
| Operating profit | $8.799 billion | $8.037 billion | +9.5% |
| Net income attributable to CVS Health | $4.644 billion | $4.592 billion | +1.1% |
| Diluted EPS | $3.96 | $3.75 | +5.6% |
| Long-term debt, year-end | $11.695 billion | $12.841 billion | Down $1.146 billion |
| Total assets, year-end | $74.252 billion | $71.526 billion | +3.8% |
| Total shareholders’ equity, year-end | $37.963 billion | $37.938 billion | Approximately flat |
Gross margin was approximately 18.2% versus 18.8% in 2013; operating margin was approximately 6.3% in both years; net margin was approximately 3.3% versus 3.6%. FY2014 included a $521 million loss on early extinguishment of debt, compared with none in 2013. The supplied filing text does not provide clear cash-flow totals, cash balances, current liabilities, or liquidity ratios.
Material changes and capital allocation
- Coram, a major infusion-services provider, was acquired in January 2014, expanding specialty infusion and enteral nutrition capabilities.
- CVS and Cardinal Health formed Red Oak Sourcing, a 50/50 generic-drug sourcing venture with a ten-year initial term. CVS consolidates the entity; Cardinal’s required payments to CVS began in October 2014.
- CVS repurchased 51.4 million shares for approximately $4.0 billion in 2014. At year-end, approximately $12.7 billion remained available under the 2014 and 2013 repurchase programs.
- Annual dividends rose to $1.10 per share from $0.90. The board authorized a new $10 billion repurchase program in December 2014.
Outlook, risks, and unusual items
- Management expected approximately 2% retail store square-footage growth in 2015. The supplied text does not provide clear earnings or revenue guidance.
- Management describes competition and reimbursement pressure in both PBM and retail pharmacy, including client demands for lower prices, generic-drug pricing pressure, and greater sharing of manufacturer rebates.
- Key exposures include extensive and changing health-care regulation, Medicare Part D and ACA changes, PBM client renewals and retention, litigation and government audits, data-security and systems disruptions, and prescription-drug supply, safety, and pricing changes.
- Revenue is generally not highly seasonal, but front-store sales are stronger around the December holidays; cough, cold, and flu season and weather can affect results. Medicare Part D benefit design also affects quarterly earnings and cash flows.
- The company reported disclosure controls as adequate and effective at a reasonable-assurance level, with no material fourth-quarter changes in internal control over financial reporting.
Important facts for investors to verify
- Review the incorporated MD&A and audited statements for segment results, operating cash flow, capital expenditures, cash and short-term borrowings, and a fuller liquidity assessment.
- Examine the $521 million debt-extinguishment charge and the financing and integration effects of the Coram acquisition.
- Assess whether revenue growth converts into sustained profit and margin growth amid reimbursement and rebate pressure.
- Check the status and terms of share repurchases, the January 2015 accelerated repurchase, and the company’s capacity to fund buybacks and dividends.
- Review the incorporated legal-contingency disclosures and regulatory developments, particularly matters affecting PBM practices, Medicare Part D, pharmacy networks, and privacy.